{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:03:11Z","timestamp":1787853791550,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["5 T32 AR007279-39"],"award-info":[{"award-number":["5 T32 AR007279-39"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ajoc.2021.101104","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T10:46:49Z","timestamp":1619002009000},"page":"101104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Tofacitinib for refractory ocular mucous membrane pemphigoid"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5979-2917","authenticated-orcid":false,"given":"Hayley","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4892-4195","authenticated-orcid":false,"given":"Grace L.","family":"Paley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Brasington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Custer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd P.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8724-3176","authenticated-orcid":false,"given":"Michael A.","family":"Paley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2021.101104_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ophtha.2017.10.004","article-title":"Mucous membrane pemphigoid with ocular involvement: the clinical phenotype and its relationship to direct immunofluorescence findings","volume":"125","author":"Ong","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2021.101104_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2021.101104_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40123-019-0164-z","article-title":"Ocular mucous membrane pemphigoid: current state of pathophysiology, diagnostics and treatment","volume":"8","author":"Georgoudis","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ajoc.2021.101104_bib4","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ajoc.2021.101104_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ajoc.2018.03.018","article-title":"Adrenocorticotropic hormone analogue as novel treatment regimen in ocular cicatricial pemphigoid","volume":"10","author":"Sharon","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ajoc.2021.101104_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.autrev.2019.02.005","article-title":"Pemphigus and mucous membrane pemphigoid: an update from diagnosis to therapy","volume":"18","author":"Buonavoglia","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ajoc.2021.101104_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2021.101104_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2021.101104_bib9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2021.101104_bib10","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2021.101104_bib11","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajoc.2021.101104_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.ajoc.2021.101104_bib13","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajoc.2021.101104_bib14","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.4049\/jimmunol.165.5.2824","article-title":"The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4","volume":"165","author":"Bhol","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ajoc.2021.101104_bib15","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1167\/iovs.11-9322","article-title":"Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients","volume":"53","author":"Suelves","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajoc.2021.101104_bib16","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajoc.2021.101104_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bjd.12041","article-title":"Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid","volume":"168","author":"Munyangango","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ajoc.2021.101104_bib18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.ajoc.2021.101104_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2021.101104_bib20","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajoc.2021.101104_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ajoc.2021.101104_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ajoc.2021.101104_bib23","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of Janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajoc.2021.101104_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993621001134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993621001134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:59:31Z","timestamp":1762527571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993621001134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":24,"alternative-id":["S2451993621001134"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2021.101104","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib for refractory ocular mucous membrane pemphigoid","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2021.101104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101104"}}